Jefferies Initiates Coverage On First Advantage with Buy Rating
Jefferies initiates coverage on First Advantage (NASDAQ:FA) with a Buy rating.
Morgan Stanley Initiates Coverage On GoDaddy with Equal-Weight Rating, Announces Price Target of $95
Morgan Stanley initiates coverage on GoDaddy (NYSE:GDDY) with a Equal-Weight rating and announces Price Target of $95.
Wolfe Research Initiates Coverage On Bright Health Gr with Peer Perform Rating, Announces Price Target of $15
Wolfe Research analyst Justin Lake initiates coverage on Bright Health Gr (NYSE:BHG) with a Peer Perform rating and announces Price Target of $15.
Deutsche Bank Initiates Coverage On Confluent with Hold Rating, Announces Price Target of $37
Deutsche Bank analyst Patrick Colville initiates coverage on Confluent (NASDAQ:CFLT) with a Hold rating and announces Price Target of $37.
Morgan Stanley Initiates Coverage On Sprinklr with Equal-Weight Rating, Announces Price Target of $22
Morgan Stanley analyst Stan Zlotsky initiates coverage on Sprinklr (NYSE:CXM) with a Equal-Weight rating and announces Price Target of $22.
Morgan Stanley Initiates Coverage On Wix.com with Overweight Rating, Announces Price Target of $339
Morgan Stanley initiates coverage on Wix.com (NASDAQ:WIX) with a Overweight rating and announces Price Target of $339.
Morgan Stanley Initiates Coverage On Confluent with Equal-Weight Rating, Announces Price Target of $45
Morgan Stanley analyst Sanjit Singh initiates coverage on Confluent (NASDAQ:CFLT) with a Equal-Weight rating and announces Price Target of $45.
HC Wainwright & Co. Initiates Coverage On BrainsWay with Buy Rating, Announces Price Target of $17
HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on BrainsWay (NASDAQ:BWAY) with a Buy rating and announces Price Target of $17.
HC Wainwright & Co. Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $30
HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on Spruce Biosciences (NASDAQ:SPRB) with a Buy rating and announces Price Target of $30.
SVB Leerink Initiates Coverage On Doximity with Outperform Rating, Announces Price Target of $65
SVB Leerink analyst Stephanie Davis initiates coverage on Doximity (NYSE:DOCS) with a Outperform rating and announces Price Target of $65.